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Abstract 
Antipyretic drugs are routinely taken by most people at the first sign of a fever, but the 
symptomatic relief achieved with these drugs comes with the price of putting out a host 
defense response known to aid the immune system in the clearance of pathogens. This may 
be a steep price to pay when lives are at stake amid the turmoil of the COVID-19 pandemic. 
Here, experimental and clinical data are discussed in light of the notion that fever is 
particularly adaptive in the early, less severe stages of an infection, when the benefits of a 
raised body temperature to immunity far exceed its costs to the host. It is, therefore, 
reasonable to advise that allowing fever to run its natural course for a few days after the onset 
of symptoms in COVID-19 may reduce the risk of long-lasting infection and, consequently, 
the risk of complications.  
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Antipyretic drugs are readily available as over-the-counter medication, being taken routinely 
by most people at the first sign of a fever. But the symptomatic relief achieved with these 
drugs comes with the price of putting out a host defense response that has evolved for 
millions of years to aid the immune system in the clearance of pathogens1,2. While it may be 
ok to pay this price in unthreatening infections such as a regular cold or a mild flu, the 
situation may be different when lives are at stake amid the uncertainty of the COVID-19 
pandemic.  
 Animal studies provide substantial support for a role of fever in survival, with it being 
particularly adaptive in the early, less severe stages of an infection, when the benefits of a 
raised body temperature to immunity far exceed its costs to the host3. Albeit less compelling, 
clinical evidence is also consistent with this notion. In a prospective trial in trauma patients, 
an aggressive antipyretic protocol strongly tended to increase the risk of acquiring an 
infection and developing complications, which prompted interruption of the trial after the 
first interim analysis of the data4. Furthermore, two randomized, double-blind, placebo-
controlled trials in rhinovirus-infected volunteers have shown that the use of aspirin, 
acetaminophen or ibuprofen is associated with increased or prolonged viral shedding5,6. In 
one of those trials5, aspirin and acetaminophen were further shown to suppress the 
neutralizing antibody response and, paradoxically, worsen nasal symptoms. These drugs are 
not identical with regard to their effects on local inflammation, but have the suppression of 
fever as a common denominator. And although fever was thought to be occasional in the 
rhinovirus-infected volunteers, infrequent measures of body temperature (no more than four 
times a day) are likely to have underestimated the prevalence of low-grade fever in those 
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trials. Indeed, many of the placebo-treated volunteers reported chilliness6, a behavior known 
to be linked with development of fever.  
Therefore, it is plausible to advise that suppression of fever early in the course of 
COVID-19 may increase the risk of long-lasting infection and, consequently, the risk of 
complications. It is also plausible to expect that antipyresis can weaken the development of 
antibody-dependent herd immunity, which, together with an enhancement in viral shedding, 
can favor the spread of the disease in the population. These arguments call further attention 
the recent warning to avoid ibuprofen in COVID-19. The warning was based on the effects 
exerted by the drug at the site of infection, be that the suppression of inflammation7 or the 
facilitation of ACE2-dependent targeting of host cells by the SARS-CoV-2 virus8. However, 
it cannot be ignored that the impacts of ibuprofen on COVID-19 may also be related to 
antipyresis, in which case recommending the use of alternate antipyretic drugs such as 
acetaminophen and aspirin may not suit the patients’ needs in terms of immunity.  
 The positive association between age and the risk of complications in COVID-19 9 is 
another aspect that can be looked upon from the perspective of fever as a host-defense 
response. Humans and experimental animals are known to mount less pronounced fevers as 
they age, with fever being completely absent in 20%-30% of elderly patients harboring a 
serious infections10. While the mechanisms underlying the suppression of fever in the elderly 
are still poorly understood, an experimental study provides evidence that this phenomenon 
may be restricted to the autonomic mechanisms of fever, with the behavioral mechanisms 
being spared to the extent that old rats regain the ability to develop fever if given the chance 
to move to a warmer environment11. If the same thermoeffector pattern occurs in humans, it 
Fever, antipyresis and COVID-19  page 4 
 
This article is a preprint and has not been peer reviewed. It reports new medical research or thought 
that has yet to be evaluated and so should not be used to guide clinical practice.  
 
Copyright © 2020 by Alexandre A. Steiner. Posted on Annals of Family Medicine COVID-19 Collection 
courtesy of Alexandre A. Steiner. 
 
 
may open a therapeutic opportunity. More specifically, if an elderly person with respiratory 
symptoms complains of chilliness, perhaps it would be more adequate to provide him or her 
with warmth than to seek symptom relief with drugs.  
The question then arises as to why so many people are afraid of fever. It has been 
documented that fever phobia is based on unrealistic concerns and misconceptions that have 
persisted in our culture despite decades of research on the true nature of fever12. The 
perception that body temperature will reach dangerous levels if fever is not treated is 
unsubstantiated by scientific evidence. On the contrary, the available evidence indicates that 
body temperature is precisely regulated during fever, and that endogenous antipyretic 
mechanisms are at work to prevent excessive rises in body temperature. Accordingly, the 
body temperature of infected patients usually stays around 38.0-39.5ºC, rarely reaching 40-
41°C and never exceeding this ceiling. Within this physiological range, the temperature rise 
per se has never been shown to be harmful to neurons or other cellular phenotypes. In young 
children, febrile seizure is a concern, but it must be considered that only a very small fraction 
of the children are predisposed to this condition, that febrile seizures are usually self-limiting 
and benign, and, what is more, that the preemptive use of antipyretic drugs may be ineffective 
at preventing the seizures13.  
Recognizing the value of fever in the early stages of an infection does not imply that 
fever has no costs, but the available evidence indicates that the costs of fever outweigh its 
benefits only at more advanced and severe stages of infection3, typically when patients are 
hospitalized because of cardiovascular or respiratory complications14,15. In such states of 
compromised physiological fitness (sepsis), the energetic cost of fever may be too much for 
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the host to bear, and, additionally, fever may heighten the maladaptive inflammation 
underlying the complications. Interestingly, it often happens that fever is replaced with a self-
limiting, spontaneous form of hypothermia in severe sepsis16, which, at least in experimental 
animals, appears to be launched by the host as an alternate defense strategy aimed at 
tolerating the pathogen while preserving vital bodily functions3. This dichotomy in the 
thermal adaptation of critically ill patients may underlie the controversial results obtained in 
some trials on the use of antipyresis in this subset of patients4,14,17. More refined strategies of 
patient stratification, perhaps involving temperature trajectories18, may help to solve this 
matter. But regardless of how complex the situation may be with critically ill patients, the 
situation is unquestionably less complex when an infection such as COVID-19 is at its 
inception, and competing demands are not at play to offset the value of fever to immunity.  
Taken together, the lines of evidence discussed herein call attention to the value of 
fever as a host defense strategy and its possible implications to COVID-19. Prioritizing 
symptom relief over host immunity in the early stages of a potentially life-threatening 
infection may not be working in our favor in the COVID-19 pandemic. In this moment of 
uncertainty and crisis, it may be proper to break cultural habits and advise against the use of 
antipyretic drugs for at least a few days after the onset of symptoms. This recommendation is 
based on lessons learned from studies on the pathophysiology of other infectious diseases, 
and does not eliminate the need for placebo-controlled studies specifically tailored to 
COVID-19. Such studies are likely to be quite challenging for requiring patient enrollment at 
the earliest sign of infection, as well as adherence to fever management protocols in an 
outpatient setting, but those challenges certainly do not undermine their importance.  
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